On Monday shares of Tobira Therapeutics, Inc. (NASDAQ:TBRA) closed at $13.97. Tobira Therapeutics, Inc. (NASDAQ:TBRA) announced on 4 May, the completion of its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, through May 4). In conjunction with the closing of the merger, Tobira raised $40 million of common stock from a combination of new investors and all current Tobira institutional investors, including the previously announced $13 million in debt that converted to common stock in this closing.
PTC Therapeutics, Inc. (NASDAQ:PTCT) in last trading activity decreased -0.19% to close at $51.99. Company weekly performance is -5.28% while its quarterly performance stands at -3.42%. PTC Therapeutics, Inc. (NASDAQ:PTCT) is -33.96% away from its 52 week high. PTC Therapeutics, Inc. (NASDAQ:PTCT) on 11 May, announced it has launched STRIVE (Strategies to Realize Innovation, Vision and Empowerment), an awards program aimed at providing funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates.
On Monday shares of Johnson & Johnson (NYSE:JNJ) closed at $103.42. Company’s sales growth for last 5 years was 3.70% and EPS growth for next 5 years is recorded as 5.13%. The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca (NYSE:AZN), Johnson & Johnson (NYSE:JNJ) and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The oral drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine.
Dex Media, Inc. (NASDAQ:DXM) has 0.70% insider ownership while its institutional ownership stands at 75.00%. In last trading activity company’s stock closed at $1.12. On 8 May, Dex Media Inc (NASDAQ:DXM) declared the launch of its new customer relationship administration platform, DexLnk.
On last trading day Stemline Therapeutics, Inc. (NASDAQ:STML) decreased -0.07% to close at $13.42. Its volatility for the week is 4.88% while volatility for the month is 5.36%. STML’s EPS growth for past 5 years was -16.90%. Stemline Therapeutics, Inc. (NASDAQ:STML) monthly performance is -16.70%. On 14 May, Stemline Therapeutics, Inc. (NASDAQ:STML), announced that Ivan Bergstein, M.D., Stemline’s CEO, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 2:30 PM ET.